Why the study?
Does inhibition of PKC-beta or leptin receptor signaling reverse PVAT-induced coronary endothelial dysfunction in metabolic syndrome?
Does inhibition of PKC-beta or leptin receptor signaling reverse PVAT-induced coronary endothelial dysfunction in metabolic syndrome?
Epicardial PVAT-derived leptin exacerbates coronary endothelial dysfunction in metabolic syndrome via a PKC-beta-dependent pathway, highlighting a potential mechanism for obesity-related coronary atherogenesis.
Answers are grounded in this paper and cite their sources.
Highlights leptin-PKC-beta pathway in MetS endothelial dysfunction; hypothesis-generating in swine and should not change practice.
OBJECTIVE: Factors released by perivascular adipose tissue (PVAT) disrupt coronary endothelial function via phosphorylation of endothelial NO synthase by protein kinase C (PKC)-beta. However, our understanding of how PVAT potentially contributes to coronary disease as a complication of obesity/metabolic syndrome (MetS) remains limited. The current study investigated whether PVAT-derived leptin impairs coronary vascular function via PKC-beta in MetS. METHODS AND RESULTS: Coronary arteries with and without PVAT were collected from lean or MetS Ossabaw miniature swine for isometric tension studies. Endothelial-dependent vasodilation to bradykinin was significantly reduced in MetS. PVAT did not affect bradykinin-mediated dilation in arteries from lean swine but significantly exacerbated endothelial dysfunction in arteries from MetS swine. PVAT-induced impairment was reversed by inhibition of either PKC-beta with ruboxistaurin (Eli Lilly and Company, Indianapolis, Ind) or leptin receptor signaling with a recombinant, pegylated leptin antagonist. Western blot and immunohistochemical analyses demonstrated increased PVAT-derived leptin and coronary leptin receptor density with MetS. Coronary PKC-beta activity was increased in both MetS arteries exposed to PVAT and lean arteries exposed to leptin. Finally, leptin-induced endothelial dysfunction was reversed by ruboxistaurin. CONCLUSIONS: Increases in epicardial PVAT leptin exacerbate coronary endothelial dysfunction in MetS via a PKC-beta-dependent pathway. These findings implicate PVAT-derived leptin as a potential contributor to coronary atherogenesis in MetS.
No takes yet. Share an insight, caveat, or question.
Payne et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: